跳至內容

格列齊特

維基百科,自由的百科全書
格列齊特
臨床資料
商品名英語Drug nomenclature達美康
AHFS/Drugs.comMicromedex詳細消費者藥物信息
懷孕分級
  • : C
給藥途徑口服
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物半衰期10.4小時
識別資訊
  • N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide
CAS號21187-98-4  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.040.221 編輯維基數據鏈接
化學資訊
化學式C15H21N3O3S
摩爾質量323.412 g/mol
3D模型(JSmol英語JSmol
  • O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3
  • InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) checkY
  • Key:BOVGTQGAOIONJV-UHFFFAOYSA-N checkY

格列齊特(英語:Gliclazide),商品名為達美康。是一種磺酰脲類口服抗糖尿病藥[1][2]. 格列齊特可以防止因高血糖引起的細胞凋亡,保護人體的胰島β細胞[3] 格列齊特還可以防止因2型糖尿病導致的動脈粥樣硬化(防止動脈脂肪堆積)。[4]格列齊特在中國作為一線藥物使用,應用極為廣泛,而在其他國家卻並不常用。Diamicron ( Gliclazide)

藥理

格列齊特為胰島素增泌劑,通過抑制胰島β細胞ATP-sensitive potassium channel英語ATP-sensitive potassium channel,從而促進胰島素的釋放。

引用

  1. ^ Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T. 
  2. ^ Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019. 
  3. ^ Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680. 
  4. ^ Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.